Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Introduction

Hand–Foot Syndrome (HFS), also known as palmar–plantar erythrodysesthesia, is a common reaction to Tyrosine Kinase Inhibitors (TKIs), which can often lead to discontinuation of the drug. Lenvatinib is a recently approved drug for the treatment of endometrial carcinoma, which has been proven to provide a better overall survival rate and longer duration of progression-free survival among patients with advanced endometrial cancer. Herein, we have reported a case of carcinoma endometrium with metastasis who had to discontinue the use of lenvatinib due to the adverse drug reaction.

Case Report

A 60-year-old female patient with carcinoma endometrium with metastasis, post radical hysterectomy with bilateral salpingo–oophorectomy with omentectomy, was started on tablet lenvatinib 8 mg once daily orally for 15 days. After 12 days of treatment, the patient noticed painful lesions with reddish-black discoloration over the left forearm and dorsal aspect of the left hand and fingers, and was diagnosed with lenvatinib-induced hand-foot syndrome. Lenvatinib was discontinued and tab. prednisolone 30mg was taken orally. The reaction subsided after five days.

Conclusion

Hand-foot syndrome is one of the commonest ADRs due to the use of lenvatinib. Lenvatinib is an oral formulation that patients can take at their homes. Hence, educating patients regarding the HFS is important so that they report it to the treating physicians on time. It is also essential to educate patients regarding the precautions to be taken to avoid hand-foot syndrome. This will help the physicians with the early discontinuation and appropriate treatment with corticosteroids, which will help in improving the quality of life of the patients already suffering from cancer.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863281030240304105117
2025-05-01
2025-10-02

  • From This Site

    /content/journals/cds/10.2174/0115748863281030240304105117
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Wai Ling KhooT.S. RehmanA. OlynykJ.K. Tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma.Hepatocellular Carcinoma. Brisbane Tirnitz-Parker JEE Codon Publications201910.15586/hepatocellularcarcinoma.2019.ch7
     [Google Scholar]
  2. de QueirozMVR de MedeirosACTR ToledoSP de Abreu SarmenghiKD de VasconcellosVF Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation.Ecancermedicalscience202216139010.3332/ecancer.2022.1390
     [Google Scholar]
  3. SaifMW ElfikyAA Identifying and treating fluoropyrimidine- associated hand-and-foot syndrome in white and nonwhite patients.J. Support. Oncol.20077337343
     [Google Scholar]
  4. CTCAE v5 November 27, 2017. Common terminology criteria for adverse events. national cancer institute.2017Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
  5. VanDoorn L VeelenturfS BinkhorstL Capecitabine and the risk of fingerprint loss.JAMA Oncol20173122123
     [Google Scholar]
  6. Lenvatinib FDA labelAvailable from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206947s021lbl.pdf
    [Google Scholar]
  7. ScheithauerW. BlumJ. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.Oncology20041891161116815471200
     [Google Scholar]
  8. LipworthA.D. RobertC. ZhuA.X. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib.Oncology200977525727110.1159/00025888019923864
     [Google Scholar]
  9. AkashS. BhounsuleA.S. Oral capecitabine – Can it cause the hand-foot syndrome?J. Clin. Diagn. Res.20115376786
     [Google Scholar]
  10. MilanoG. Etienne-GrimaldiM.C. MariM. LassalleS. FormentoJ.L. FrancoualM. LacourJ.P. HofmanP. Candidate mechanisms for capecitabine‐related hand–foot syndrome.Br. J. Clin. Pharmacol.2008661889510.1111/j.1365‑2125.2008.03159.x18341672
     [Google Scholar]
  11. ClarkA.S. VahdatL.T. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies.Support. Cancer Ther.20041421321810.3816/SCT.2004.n.01318628145
     [Google Scholar]
  12. PaddaI.S. ParmarM. Lenvatinib.Updated 2023 Jun 3In: StatPearls.InternetTreasure Island, FLStatPearls Publishing2023https://www.ncbi.nlm.nih.gov/books/NBK567768/
     [Google Scholar]
  13. KatoY. TabataK. KimuraT. Yachie-KinoshitaA. OzawaY. YamadaK. ItoJ. TachinoS. HoriY. MatsukiM. MatsuokaY. GhoshS. KitanoH. NomotoK. MatsuiJ. FunahashiY. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.PLoS One2019142e021251310.1371/journal.pone.021251330811474
     [Google Scholar]
  14. HigashiyamaT. SuginoK. HaraH. ItoK. NakashimaN. OnodaN. ToriM. KatohH. KiyotaN. OtaI. SuganumaN. HibiY. NemotoT. TakahashiS. YaneK. IojiT. KojimaS. KanedaH. SugitaniI. TaharaM. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).Eur. J. Cancer202217321021810.1016/j.ejca.2022.06.04435932627
     [Google Scholar]
  15. MakkerV. ColomboN. Casado HerráezA. SantinA.D. ColombaE. MillerD.S. FujiwaraK. PignataS. Baron-HayS. Ray-CoquardI. Shapira-FrommerR. UshijimaK. SakataJ. YonemoriK. KimY.M. GuerraE.M. SanliU.A. McCormackM.M. SmithA.D. KeefeS. BirdS. DuttaL. OrlowskiR.J. LorussoD. Study 309–KEYNOTE-775 Investigators Lenvatinib plus pembrolizumab for advanced endometrial cancer.N. Engl. J. Med.2022386543744810.1056/NEJMoa210833035045221
     [Google Scholar]
  16. MillerK.K. GorceyL. McLellanB.N. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management.J. Am. Acad. Dermatol.201471478779410.1016/j.jaad.2014.03.01924795111
     [Google Scholar]
  17. LiuH.L. HungC.T. Dramatic improvement of lenvatinib‐induced hand‐foot skin reaction with 7‐day oral prednisolone and acitretin.Australas. J. Dermatol.2022632e181e18210.1111/ajd.1381535312036
     [Google Scholar]
  18. YoshidaY. SasaokaS. TanakaM. MatsumotoK. InoueM. SatakeR. ShimadaK. MukaiR. SuzukiT. IwataM. GotoF. MoriT. MoriK. YoshimuraT. NakamuraM. Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database.Ther. Adv. Drug Saf.20221310.1177/2042098622110196335646307
     [Google Scholar]
  19. McLellanB. KerrH. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.Dermatol. Ther.201124439640010.1111/j.1529‑8019.2011.01435.x21910797
     [Google Scholar]
  20. ChildressJ. LokichJ. Cutaneous hand and foot toxicity associated with cancer chemotherapy.Am. J. Clin. Oncol.200326543543610.1097/01.coc.0000026486.56886.1814528066
     [Google Scholar]
  21. Rodríguez-LombaE. Molina-LópezI. Suárez-FernándezR. Baniandrés-RodríguezO. Periarticular thenar erythema and onycholysis syndrome: A manifestation of taxane-induced cutaneous toxicity.Actas Dermo-Sifiliográficas2017108659559710.1016/j.adengl.2017.05.00228117052
     [Google Scholar]
  22. RzepeckiA.K. FrancoL. McLellanB.N. PATEO syndrome: Periarticular thenar erythema with onycholysis.Acta Oncol.201857799199210.1080/0284186X.2017.142091229283012
     [Google Scholar]
  23. FerreiraO. BaudrierT. MotaA. DuarteA.F. AzevedoF. Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas.Cutan. Ocul. Toxicol.201029429629910.3109/15569527.2010.49839720608863
     [Google Scholar]
  24. ChewL. ChuenV.S.L. Cutaneous reaction associated with weekly docetaxel administration.J. Oncol. Pharm. Pract.2009151293410.1177/107815520809611118753180
     [Google Scholar]
  25. ChuC-Y. YangC-H. YangC-Y. HsiaoG-H. ChiuH-C. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel.Br. J. Dermatol.2000142480881110.1046/j.1365‑2133.2000.03432.x10792238
     [Google Scholar]
  26. CutlerL. WangH. KimG. ChiuM. Fixed erythrodysesthesia plaques at sites of intravenous docetaxel infusion: An unusual cutaneous reaction to chemotherapy.Int. J. Dermatol.2022618e316e31710.1111/ijd.1579834351630
     [Google Scholar]
  27. AndersonR. JatoiA. RobertC. WoodL.S. KeatingK.N. LacoutureM.E. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).Oncologist200914329130210.1634/theoncologist.2008‑023719276294
     [Google Scholar]
  28. LacoutureM.E. WuS. RobertC. AtkinsM.B. KongH.H. GuitartJ. GarbeC. HauschildA. PuzanovI. AlexandrescuD.T. AndersonR.T. WoodL. DutcherJ.P. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.Oncologist20081391001101110.1634/theoncologist.2008‑013118779536
     [Google Scholar]
  29. EdwardsS.J. Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer.Semin. Oncol. Nurs.2003193193910.1016/S0749‑2081(03)00059‑712971248
     [Google Scholar]
  30. World Health Organization. (n.d.)WHO causality assessment of suspected adverse reactions. https://www.who.int/docs/defaultsource/medicines/pharmacovigilance/whocausality-assessment.pdf Accessed on 29 February 2024.
  31. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4].Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/
/content/journals/cds/10.2174/0115748863281030240304105117
Loading
Hand Foot Syndrome Induced by Lenvatinib - A Case Report
Curr Drug Saf 20, 224 (2025); https://doi.org/10.2174/0115748863281030240304105117
/content/journals/cds/10.2174/0115748863281030240304105117
/content/journals/cds/10.2174/0115748863281030240304105117
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): adverse drug reaction; case report; Hand-foot syndrome; lenvatinib; palmar–plantar erythrodysesthesia; pharmacovigilance; tyrosine kinase inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test